Actinium-225, aka "the world's rarest drug"
(Full access for Members only)
Actinium-225, aka "the world's rarest drug"
10 October 2024
What readers said about this report
The global hunt is on for Actinium-225, the rare nuclear isotope that could redefine cancer care.
"Ac-225" does not occur naturally. It can, however, be produced from radium.
The trouble is, radium is also extremely rare. Production mostly took place during the Cold War, when it was used for nuclear bombs. However, only a few kilograms of the material were produced, and production was subsequently stopped altogether.
Luckily, one Western European nation had 100-200g of the stuff tucked away in a basement.
One publicly listed Western European company will now become the key beneficiary of the find. This company signed an agreement with the domestic government to use the radium for producing Ac-225.
It is not a start-up company, but a world market leader in cancer therapy. Over the past decades, it has built a nearly 50% global market share in its particular form of cancer therapy.
The stock would be cheap anyway and a buy ahead of a new growth cycle, but now the Ac-225 potential comes on top of it.
It's a mind-boggling story, even by the standards of Undervalued-Shares.com.
Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.
What readers said about this report
Adam R.
October 2024
What an amazing writeup...and checks all the boxes for an interesting investment. Thanks!
Alex F.
October 2024
Just read your radium piece - what an interesting report! ... Definitely a persuasive case, and in a way, romantic, too.
Stephen S.
October 2024
Thanks for the report – currently reviewing – looks interesting/promising.
Ákos V.
October 2024
Your last analysis on (company name hidden by Undervalued-Shares.com) was a masterpiece again, either as an investment idea, but also for its level of elaboration, and its readibility. Thanks for that.
Jonathan T.
October 2024
Always finding the most interesting and peculiar investments. Love it! Keep up the good work.
Daniel S.
October 2024
Thank you very much. Your ability to find exciting investments always impresses me.